The WIRB stated, The Board determined that the device as used in the research study is a non-significant risk device. Kamal Sarbadhikari CEO, SensiVida Medical Technologies, Inc. said, given this important ‘green light,’ we are now poised to begin human clinical trials and are pleased that the WIRB agrees with the company’s position that our microsystems-based digital allergy test device is a non-significant risk device.
